HIGHLIGHTS
- What: This study examined the prognosis of patients with advanced and recurrent EC who received chemotherapy as adjuvant or palliative therapy by investigating progression-free survival (PFS) and overall survival (OS) to determine whether L1CAM can be a useful prognostic marker for these patients. The research team verified the loss of MSH2 or MSH6 and aberrant p53 expression using cervical swab-based gDNA and confirmed its value as a tool that can be used to layer ProMisE molecular classification based on tests and stratification.
- Who: Jung Chul Kim from the This retrospective cohort study was . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.